Search Results 121-130 of 11408 for ���������������������������:za33���24������ ������������������������ ������

  1. Publications - Konstantinos N. Lazaridis, M.D. - Mayo Clinic

    2022 May; 24(5):1062-1072. Epub 2022 Mar 21. View PubMed; Cheung AC, Juran BD, Schlicht EM, McCauley BM, Atkinson EJ, Moore R, Heimbach JK, Watt KD, Wu TT ...

  2. Publications - Rachael A. Vaubel, M.D., Ph.D. - Mayo Clinic

    2025 Feb 4; 24 (2):299-309. View PubMed; Vizcaino MA, Giannini C, Vaubel RA, Nguyen AT, Trejo-Lopez JA, Raghunathan A, Jenkins SM, Jenkins RB, Zepeda Mendoza ...

  3. A Study of the Clinical Experience and Acceptance of the Artificial Pancreas

    ... 24/7 in-home usability prior to initiating a large randomized controlled trial. Participation eligibility. Participant eligibility includes age, gender, type ...

  4. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma - Mayo Clinic

    ... 24 months) other than the disease being treated under study. The only allowed exceptions are: a) non-muscle invasive bladder cancer treated within the last 24 ...

  5. ... 24X15,"3,708.00" 278000042,39065,GRFT VSC 7X8X16X16X45,"2,060.00" 278000042,39068,GRFT PRP 3X10,"1,762.00" 278000042,39077,GRFT EXC MN BDY 23X12X12 ...

  6. Obstetrics and Gynecology - Clinical trials

    ... 24; Month 6) Visit 9 (Week 52; Month 12). Visit 10 (Week 104, Month 24). Predictive Role of Non-Invasive Glucose Assessment During Pregnancy. Rochester, Minn ...

  7. Obstetrics and Gynecology - Clinical trials

    ... 24; Month 6) Visit 9 (Week 52; Month 12). Visit 10 (Week 104, Month 24). Predictive Role of Non-Invasive Glucose Assessment During Pregnancy. Rochester, Minn ...

  8. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors - Mayo Clinic

    PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours × 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a ...

  9. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...

  10. ... 24,24, 300000000,HC 2D6 SEQUENCING,548,548, 300000002,HC 5-HTT GENE ANALYSIS,338,338, 300000004,HC ABL1 KD VARIANTS,705,850, 300000005,HC ACADS KNOWN ...